SCHEMBL4483928

SCHEMBL4483928

Cc1cc(C(=O)Nc2cccc(-c3ccc(-c4ccccc4)n3CC(=O)NC(=N)N)c2)no1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
USP2 O75604 2/20 0.48
MAPT P10636 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HSD17B10 Q99714 2/20 0.43
RAB9A P51151 5/20 0.42
TP53 P04637 3/20 0.42
KDM4E B2RXH2 1/20 0.42
GFER P55789 1/20 0.42
NPC1 O15118 3/20 0.42
GLA P06280 1/20 0.42
HTT P42858 1/20 0.42
GAA P10253 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
HPGD P15428 1/20 0.41
CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8269526 0.84 BACE1 (0.60) ALDH1A1SMN1; SMN2USP2MAPTMEN1
SCHEMBL4494345 0.84 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2USP2MAPTMEN1
SCHEMBL4472723 0.76 BACE1 (0.55) ALDH1A1KMT2AHSD17B10KDM4EHPGD
SCHEMBL4479466 0.76 BACE1 (0.55) ALDH1A1MAPTMEN1KMT2ARAB9A
SCHEMBL4478905 0.74 BACE1 (0.46) KMT2ABACE1ROCK2ROCK1
SCHEMBL4488993 0.72 BACE1 (0.71) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4495554 0.72 BACE1 (0.73) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL8267163 0.71 SMN1; SMN2 (0.88) ALDH1A1SMN1; SMN2USP2MAPTHSD17B10
SCHEMBL8266868 0.71 RAB9A (0.77) ALDH1A1SMN1; SMN2USP2MAPTHSD17B10
SCHEMBL4487598 0.71 BACE1 (0.72) ALDH1A1MAPTMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7488832-B2 e.g. N-[amino(imino)methyl]-2-[2-(4-phenoxyphenyl)-5-phenyl-1H-pyrrol-1-yl]acetamide; beta -amyloid deposits and neurofibrillary tangles; cognition activator, neurodegenerative diseases; Alzheimer's disease, Down's syndrome WYETH (US) 2009-02-10 US disclosed
US-20080287424-A1 AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS WYETH (US) 2008-11-20 US disclosed
US-20060183790-A1 Azolylacylguanidines as beta-secretase inhibitors WYETH (US) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287424-A1 AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS BACE1, BACE2, APP ALDH1A1 360/4885SMN1; SMN2 2907/4885USP2 593/4885
US-20060183790-A1 Azolylacylguanidines as beta-secretase inhibitors BACE1, BACE2, APP ALDH1A1 360/4885SMN1; SMN2 2907/4885USP2 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.